Is Fragmented Safety Data Holding Back Your Pharmacovigilance Strategy?

Pharmacovigilance has never been more data-rich—or more complex.

Today, safety information is generated from a wide range of sources, including Individual Case Safety Reports (ICSRs), clinical trials, medical information enquiries, literature surveillance, licensing partners, patient support programmes, regulatory authorities, and real-world evidence. Each source contributes valuable insights into a product’s safety profile.

Yet for many pharmaceutical and biotechnology companies, these data streams remain fragmented.

Different vendors manage different activities. Safety information is stored across multiple systems. Regional teams follow different processes and reporting structures. While each function may perform well independently, fragmentation can make it difficult to build a complete picture of product safety.

 

The Hidden Cost of Fragmentation

Many organizations have arrived at their current pharmacovigilance operating model over time.

As companies expand into new markets, acquire products, or establish licensing partnerships, new vendors and systems are often added to support specific needs. While this approach can offer flexibility in the short term, it frequently introduces complexity as operations grow.

The consequences are not always immediately visible, but they can have a significant impact on efficiency and oversight.

Limited Visibility Across the Safety Landscape

When safety data is dispersed across multiple systems and providers, obtaining a complete view of a product’s safety profile becomes increasingly challenging.

Potential safety signals may emerge across different datasets—including spontaneous reports, literature findings, medical information enquiries, or local market activities—but identifying meaningful trends requires those data sources to be connected.

Without an integrated view, organizations risk making benefit-risk decisions based on incomplete information.

Operational Complexity

Multiple vendors often mean multiple governance structures, quality systems, reporting formats, and communication pathways.

Teams spend valuable time reconciling data, coordinating across suppliers, and maintaining overlapping processes rather than focusing on activities that directly improve patient safety.

As product portfolios grow, this complexity increases, making it more difficult to scale operations efficiently.

Slower Safety Insights

Modern pharmacovigilance depends on timely access to reliable data.

Disconnected processes can delay signal detection, aggregate reporting, and regulatory decision-making. The challenge is no longer collecting safety data—it is transforming that data into actionable insight quickly enough to support informed decisions.

Why More Organizations Are Consolidating Pharmacovigilance Operations

Vendor consolidation is often associated with operational efficiency, but its greatest value extends far beyond cost savings.

By centralizing pharmacovigilance activities under a unified operating model, organizations can create a connected safety ecosystem where information flows consistently across the product lifecycle.

The benefits include:

• Improved data quality through standardized processes and a single source of truth
• Faster signal detection by integrating data from multiple safety sources
• More efficient governance with streamlined communication and oversight
• Greater consistency across global markets and regulatory requirements
• Better use of automation and advanced analytics within standardized workflows

Rather than managing disconnected activities, organizations gain the ability to generate strategic insights from their safety data.

What Should You Look for in a Global Pharmacovigilance Partner?

Consolidation is only effective when supported by a partner capable of managing both global complexity and local regulatory requirements.

When evaluating a pharmacovigilance partner, consider whether they offer:

• End-to-end pharmacovigilance support across the product lifecycle
• Global reach combined with local regulatory expertise
• Integrated safety systems and technology-enabled workflows
• Strong quality management and inspection readiness
• Strategic guidance that extends beyond transactional service delivery

The right partner should help transform pharmacovigilance from an operational necessity into a strategic capability that supports better decision-making throughout the product lifecycle.

Looking Ahead

As safety data volumes continue to grow and regulatory expectations become increasingly complex, fragmented pharmacovigilance models will become harder to sustain.

Organizations that successfully connect their safety data, processes, technology, and expertise will be better positioned to identify emerging risks earlier, improve operational efficiency, and maintain compliance across global markets.

Consolidating pharmacovigilance operations is no longer simply an outsourcing decision—it is an opportunity to strengthen visibility, improve collaboration, and unlock greater value from safety data.

Is your pharmacovigilance ecosystem helping you generate strategic insights—or creating unnecessary complexity?

Whether you’re expanding into new markets, integrating acquired products, or reassessing your operating model, the right pharmacovigilance partner can help you connect fragmented safety data into a unified, compliant, and scalable ecosystem.

Contact the PrimeVigilance team to discuss how an integrated global pharmacovigilance approach can support your organization.